RBC Capital Cuts PT on Legend Biotech Corporation (LEGN) to $62 From $66 – Here’s Why
Estimated Price Impact
Pre vs Post NewsAI Executive Summary
RBC Capital has downgraded the price target for Legend Biotech Corporation (LEGN) from $66 to $62, indicating a cautious outlook on the company's future performance. The cut in price target is attributed to concerns regarding competitive pressures in the biopharmaceutical market as well as uncertainties surrounding upcoming product pipelines. The adjustment in price target reflects the analysts' reassessment of LEGN based on recent market developments. Investors may need to reevaluate their positions on LEGN following this announcement. Overall, the sentiment appears bearish on LEGN in the short term.
Trader Insight
"Consider shorting LEGEND Biotech or waiting for a more stable entry point, as the bearish sentiment may continue to pressure the stock price."